Increased expression of the complement molecule, C5a, in NSCLC patients has been shown to activate signaling through its receptor, C5aR, and is associated with increased KLF5, GCN5, and GDF15 levels and promotion of A549 proliferation [35]. This evidence concerns the gene C5AR1 and non-small cell lung carcinoma.